Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia GlobeNewswire May 06 ...

The DISCOVER Phase 1/2a trial is an open-label, single ascending dose, 9-month study that will evaluate the safety and bioactivity of AXT107 ...

Shares of EyePoint Pharmaceuticals dropped nearly 30% premarket on Monday after the company said its experimental eye disease ...

BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company ...

Spirulina and chlorella are types of microalgae commonly taken in supplement form. They share some benefits, but they each offer unique properties.

Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – – 6:00 PM CET, Oxurion ...

EyePoint (EYPT) stock tumbled nearly 30% in premarket trading Monday after the company said a Phase 2 study for its eye drug ...

“Sight Beyond Limits”: On display through May. The Mandelbaum and Ambert Family Vision Gallery is located on the 9th floor, ...

Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with STGD1 and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration ...

Targeting a major pharmaceutical market in retinal diseases, EyePoint Pharmaceuticals has revealed that its lead drug ...

A quartet of studies presented at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting addressed ...

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month visual acuity results from patients ...